Program
tofacitinib
Also written as “CP-690,550”, “Tofacitinib” and “tofacitinib modified-release (MR) formulation”.
Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Colitis, Ulcerative · Arthritis, Psoriatic · Arthritis, Juvenile, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 881 open or running | phase 4since Mar 3, 2014 | Mar 28, 2005 | Mar 17, 2027phase 3 · NCT04624230 |
| CAGE Bio | 10 open or running | phase 2since Aug 1, 2022 | Aug 1, 2022 | none ahead |
| Johnson & Johnson | 10 open or running | phase 1since Jul 22, 2021 | Jul 22, 2021 | none ahead |
| TWi Biotechnology | 10 open or running | phase 1since Jul 7, 2020 | Jul 7, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Jun 9, 2010.
- Aug 14, 2015Phase 3 study in Arthritis, JuvenilePfizer · NCT02592434 · 225 enrolled · United States, Argentina, Australia and more
- Jul 11, 2016Phase 4 study in Arthritis, RheumatoidPfizer · NCT02831855 · 694 enrolled · United States, Australia, Belgium and more
- Nov 9, 2016Phase 3 study in Arthritis, JuvenilePfizer · NCT03000439 · 100 enrolled · United States, Argentina, Belgium and more
- Sep 11, 2017Phase 4 study in Colitis, UlcerativePfizer · NCT03281304 · 140 enrolled · United States, Belgium, Canada and more
- Mar 5, 2018Phase 3 study in Arthritis, PsoriaticPfizer · NCT03486457 · 204 enrolled · China
- Apr 11, 2018Phase 3 study in Spondylitis, AnkylosingPfizer · NCT03502616 · 270 enrolled · United States, Australia, Bulgaria and more
- Sep 30, 2019Phase 1 study in HealthyPfizer · NCT04111614 · 12 enrolled · United States
- Mar 11, 2020Phase 1 study in HealthyPfizer · NCT04338711 · 23 enrolled · United States
- May 4, 2020Phase 1 study in HealthyPfizer · NCT04403776 · 26 enrolled · China
- May 19, 20202 phase 2 studiesPfizer · NCT04413617, NCT04412252
- Jul 7, 2020TWi Biotechnology's first study: phase 1 study in Healthy SubjectsNew to TWi BiotechnologyTWi Biotechnology · NCT04468425 · 20 enrolled · Canada
- Oct 26, 2020Phase 3 study in Colitis, UlcerativePfizer · NCT04624230 · 118 enrolled · United States, Australia, Belgium and more
- Jul 22, 2021Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT04985955 · 12 enrolled · Belgium
- Aug 1, 2022CAGE Bio's first study: phase 2 study in Dermatitis, AtopicNew to CAGE BioCAGE Bio · NCT05487963 · 40 enrolled · Georgia
Ahead
- Mar 17, 2027Primary completion: phase 3 study in Colitis, UlcerativePfizer · NCT04624230
TargetBeta
“Janus Kinase (JAK) inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
Studies
The newest 60 of 91 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05487963Dermatitis, Atopic · Georgia | 2 | Completed | CAGE Bio | Jun 30, 2023 | 40 |
| NCT04985955Healthy · Belgium | 1 | Completed | Johnson & Johnson | Sep 21, 2021 | 12 |
| NCT04624230Colitis, Ulcerative · United States, Australia, Belgium and more | 3 | Active, not recruiting | Pfizer | Mar 17, 2027 | 118 |
| NCT04468425Healthy Subjects · Canada | 1 | Completed | TWi Biotechnology | Dec 21, 2020 | 20 |
| NCT04412252COVID-19 · United States | 2 | Withdrawn | Pfizer | Sep 16, 2020 | 0 |
| NCT04413617Arthritis, Rheumatoid · Bulgaria, Canada, Chile and more | 2 | Completed | Pfizer | Feb 7, 2022 | 460 |
| NCT04403776Healthy · China | 1 | Completed | Pfizer | Feb 12, 2019 | 26 |
| NCT04338711Healthy · United States | 1 | Completed | Pfizer | Sep 15, 2020 | 23 |
| NCT04111614Healthy · United States | 1 | Completed | Pfizer | Dec 12, 2019 | 12 |
| NCT03502616Spondylitis, Ankylosing · United States, Australia, Bulgaria and more | 3 | Completed | Pfizer | Dec 19, 2019 | 270 |
| NCT03486457Arthritis, Psoriatic · China | 3 | Completed | Pfizer | Apr 28, 2021 | 204 |
| NCT03281304Colitis, Ulcerative · United States, Belgium, Canada and more | 4 | Terminated | Pfizer | Feb 14, 2020 | 140 |
| NCT03000439Arthritis, Juvenile · United States, Argentina, Belgium and more | 3 | Completed | Pfizer | Mar 27, 2024 | 100 |
| NCT02831855Arthritis, Rheumatoid · United States, Australia, Belgium and more | 4 | Completed | Pfizer | Nov 19, 2018 | 694 |
| NCT02592434Arthritis, Juvenile · United States, Argentina, Australia and more | 3 | Completed | Pfizer | May 16, 2019 | 225 |
| NCT02281552Arthritis, Rheumatoid · Japan | 3 | Completed | Pfizer | Mar 15, 2017 | 209 |
| NCT02187055Rhematoid Arthritis · United States, Argentina, Australia and more | 4 | Completed | Pfizer | Dec 2016 | 1,152 |
| NCT02147587Arthritis, Rheumatoid · United States | 2 | Completed | Pfizer | Jun 2015 | 112 |
| NCT02084875Healthy · United States | 1 | Completed | Pfizer | May 25, 2014 | 24 |
| NCT02092467Arthritis, Rheumatoid · United States, Argentina, Australia and more | 4 | Completed | Pfizer | Jul 22, 2020 | 4,372 |
| NCT02001181Dermatitis, Atopic · Canada | 2 | Completed | Pfizer | Sep 2014 | 69 |
| NCT01976364Arthritis, Psoriatic · United States, Australia, Belgium and more | 3 | Completed | Pfizer | May 20, 2019 | 686 |
| NCT01882439Arthritis, Psoriatic · United States, Australia, Belgium and more | 3 | Completed | Pfizer | Apr 2016 | 395 |
| NCT01877668Arthritis, Psoriatic · United States, Australia, Belgium and more | 3 | Completed | Pfizer | Dec 18, 2015 | 422 |
| NCT01831466Psoriasis · United States, Canada, Denmark and more | 2 | Completed | Pfizer | Sep 2014 | 476 |
| NCT01815424Psoriasis · China, Korea, Republic of, Taiwan | 3 | Completed | Pfizer | Jul 2015 | 266 |
| NCT01786668Spondylitis, Ankylosing · United States, Canada, Czech Republic and more | 2 | Completed | Pfizer | Mar 2015 | 208 |
| NCT01745055Arthritis, Rheumatoid · United States | 1 | Completed | Pfizer | Jun 2006 | 12 |
| NCT01736696Psoriasis · United States | 1 | Completed | Pfizer | Apr 2004 | 59 |
| NCT01731327Healthy · Singapore | 1 | Completed | Pfizer | Dec 2012 | 20 |
| NCT01743677Healthy · Belgium, Singapore | 1 | Completed | Pfizer | Feb 7, 2008 | 60 |
| NCT01740362Renal Insufficiency · United States | 1 | Completed | Pfizer | Mar 2004 | 24 |
| NCT01710046Plaque Psoriasis · United States | 2 | Completed | Pfizer | Nov 2013 | 12 |
| NCT01710033Kidney Transplant · United States | 1 | Completed | Pfizer | Apr 2005 | 28 |
| NCT01710020Kidney Failure, Chronic · United States | 1 | Completed | Pfizer | Jun 2003 | 12 |
| NCT01599377Healthy · Singapore | 1 | Completed | Pfizer | Jul 2012 | 50 |
| NCT01513902Arthritis, Juvenile · United States, Germany, Poland and more | 1 | Completed | Pfizer | Dec 2015 | 26 |
| NCT01519089Psoriasis · Japan | 3 | Completed | Pfizer | Jan 2014 | 95 |
| NCT01500551Arthritis, Juvenile · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Feb 12, 2025 | 302 |
| NCT01499004Healthy · Singapore | 1 | Completed | Pfizer | Dec 2011 | 30 |
| NCT01470599Crohn Disease · United States, Australia, Austria and more | 2 | Completed | Pfizer | Jul 2016 | 150 |
| NCT01470612Colitis, Ulcerative · United States, Australia, Austria and more | 3 | Completed | Pfizer | Aug 6, 2020 | 944 |
| NCT01465763Colitis, Ulcerative · United States, Australia, Austria and more | 3 | Completed | Pfizer | May 2015 | 614 |
| NCT01458951Colitis, Ulcerative · United States, Australia, Austria and more | 3 | Completed | Pfizer | May 2015 | 547 |
| NCT01458574Colitis, Ulcerative · United States, Australia, Austria and more | 3 | Completed | Pfizer | May 27, 2016 | 593 |
| NCT01393899Crohn Disease · United States, Australia, Austria and more | 2 | Completed | Pfizer | Jul 2015 | 180 |
| NCT01393626Crohn Disease · United States, Australia, Austria and more | 2 | Completed | Pfizer | Feb 2015 | 280 |
| NCT01359150Arthritis, Rheumatoid · United States, Poland | 2 | Completed | Pfizer | Feb 2012 | 223 |
| NCT01309737Psoriasis · United States, Canada, Colombia and more | 3 | Completed | Pfizer | Apr 2013 | 960 |
| NCT01276639Psoriasis · United States, Canada, Colombia and more | 3 | Completed | Pfizer | Apr 2013 | 901 |
| NCT01246583Psoriasis · United States, Canada | 2 | Completed | Pfizer | Nov 29, 2011 | 71 |
| NCT01262118Arthritis, Rheumatoid · United States, Hungary | 1 | Completed | Pfizer | Jan 2012 | 69 |
| NCT01241591Psoriasis · Argentina, Austria, Belgium and more | 3 | Completed | Pfizer | Jan 2013 | 1,101 |
| NCT01226680Keratoconjunctivitis Sicca | 2 | Withdrawn | Pfizer | Oct 19, 2012 | 0 |
| NCT01204112Healthy · United States | 1 | Completed | Pfizer | Oct 2010 | 12 |
| NCT01186744Psoriasis · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Jan 2013 | 666 |
| NCT01185184Healthy · Singapore | 1 | Completed | Pfizer | Aug 2010 | 12 |
| NCT01164579Arthritis, Rheumatoid · United States, Argentina, Chile and more | 2 | Completed | Pfizer | Nov 2013 | 109 |
| NCT01163253Psoriasis · United States, Argentina, Australia and more | 3 | Terminated | Pfizer | Jun 2016 | 2,867 |
| NCT01143805Arthritis, Rheumatoid · Singapore | 1 | Completed | Pfizer | Aug 2010 | 12 |
How it is read
Names in the registry
- “CP-690,550”, 102 entries
- “Tofacitinib”, 19 entries
- “tofacitinib”, 11 entries
- “tofacitinib modified-release (MR) formulation”, 4 entries
- “CP- 690 550”, 4 entries
Codes read as this program: CP690.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 27 studies
- Psoriasis, 12 studies
- Colitis, Ulcerative, 8 studies
- Arthritis, Psoriatic, 5 studies
- Arthritis, Juvenile, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.